Boris Pasche, President and CEO of the Karmanos Cancer Institute, shared a post by Karmanos Cancer Institute on LinkedIn:
“Karmanos Cancer Institute, at the forefront of pioneering theranostic techniques and FDA-approved radiopharmaceutical treatments like Pluvicto and Lutathera, recently achieved a milestone with the installation of a cutting-edge SPEC/CT machine at our Detroit cancer center. This advancement signifies a significant step towards delivering personalized, state-of-the-art care to our patients.”